Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Inovio Pharma (INO)

Inovio Pharma (INO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 128,522
  • Shares Outstanding, K 25,964
  • Annual Sales, $ 830 K
  • Annual Income, $ -135,120 K
  • EBIT $ -117 M
  • EBITDA $ -106 M
  • 60-Month Beta 0.83
  • Price/Sales 160.71
  • Price/Cash Flow N/A
  • Price/Book 1.38

Options Overview Details

View History
  • Implied Volatility 102.61% ( -29.87%)
  • Historical Volatility 44.77%
  • IV Percentile 45%
  • IV Rank 7.53%
  • IV High 1,134.03% on 12/11/23
  • IV Low 18.57% on 08/26/24
  • Put/Call Vol Ratio 0.07
  • Today's Volume 939
  • Volume Avg (30-Day) 126
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 14,007
  • Open Int (30-Day) 13,897

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -1.20
  • Number of Estimates 3
  • High Estimate -1.12
  • Low Estimate -1.24
  • Prior Year -1.08
  • Growth Rate Est. (year over year) -11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.76 +0.21%
on 11/14/24
5.83 -18.18%
on 10/21/24
-0.93 (-16.32%)
since 10/14/24
3-Month
4.76 +0.21%
on 11/14/24
8.13 -41.33%
on 08/15/24
-3.05 (-39.00%)
since 08/14/24
52-Week
4.20 +13.57%
on 12/01/23
14.75 -67.66%
on 04/01/24
+0.27 (+6.00%)
since 11/14/23

Most Recent Stories

More News
Inovio: Q3 Earnings Snapshot

Inovio: Q3 Earnings Snapshot

INO : 4.77 (-3.64%)
Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching

Less stringent requirements in pharmaceuticals and biotechnology could help biotechs by prompting accelerated drug approvals.

SRNE : 0.0038 (+2.70%)
TNXP : 0.1400 (-0.85%)
IBB : 140.09 (-2.58%)
JAGX : 1.0400 (+5.31%)
NVAX : 7.22 (-7.02%)
INO : 4.77 (-3.64%)
GILD : 92.11 (-0.56%)
MRNA : 39.77 (-5.62%)
VXRT : 0.6300 (-11.80%)
IBIO : 2.15 (-7.33%)
XBI : 96.96 (-3.05%)
PFE : 26.02 (-2.62%)
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031

EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END

SBFM : 2.57 (+0.39%)
MRNA : 39.77 (-5.62%)
PFE : 26.02 (-2.62%)
INO : 4.77 (-3.64%)
VIR : 8.64 (-3.79%)
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031

SBFM : 2.57 (+0.39%)
MRNA : 39.77 (-5.62%)
PFE : 26.02 (-2.62%)
INO : 4.77 (-3.64%)
VIR : 8.64 (-3.79%)
Inovio Pharmaceuticals (INO) Q2 2024 Earnings Call Transcript

INO earnings call for the period ending June 30, 2024.

INO : 4.77 (-3.64%)
Inovio: Q2 Earnings Snapshot

Inovio: Q2 Earnings Snapshot

INO : 4.77 (-3.64%)
5 Analyst-Approved Stocks Set to Join the Russell Microcap Index

As a part of the annual Russell index rebalancing, here are five stocks set to join the Russell Microcap Index this year, which analysts have tagged with consensus ‘buy’ ratings.

HUT : 23.14 (-6.62%)
^BTCUSD : 87,536.45 (-0.78%)
URG : 1.2400 (+4.20%)
LUNR : 10.23 (-13.01%)
INO : 4.77 (-3.64%)
AISP : 3.69 (-1.34%)
Better Buy: Inovio Pharmaceuticals vs. Novavax

Both biotechs have been struggling for a while, but there might be some hope for them.

PFE : 26.02 (-2.62%)
NVAX : 7.22 (-7.02%)
INO : 4.77 (-3.64%)
Inovio Pharmaceuticals (INO) Q1 2024 Earnings Call Transcript

INO earnings call for the period ending March 31, 2024.

INO : 4.77 (-3.64%)
Inovio: Q1 Earnings Snapshot

Inovio: Q1 Earnings Snapshot

INO : 4.77 (-3.64%)

Business Summary

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled...

See More

Key Turning Points

3rd Resistance Point 5.25
2nd Resistance Point 5.15
1st Resistance Point 4.96
Last Price 4.77
1st Support Level 4.67
2nd Support Level 4.57
3rd Support Level 4.38

See More

52-Week High 14.75
Fibonacci 61.8% 10.72
Fibonacci 50% 9.47
Fibonacci 38.2% 8.23
Last Price 4.77
52-Week Low 4.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar